Company Profile

Macrogenics Inc
Profile last edited on: 4/5/22      CAGE: 3PTZ3      UEI: V6KCS3B53JN8

Business Identifier: Antibody-based therapies for autoimmune and infectious diseases and cancer
Year Founded
2000
First Award
2002
Latest Award
2010
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

9640 Medical Center Drive
Rockville, MD 20850
   (301) 251-5172
   info@macrogenics.com
   www.macrogenics.com
Location: Multiple
Congr. District: 08
County: Montgomery

Public Profile

Macrogenics Inc is focused on exploiting the mechanisms by which cytotoxic antibodies mediate cell killing both for the development and improvement of existing therapeutic antibodies for the treatment of cancers and the development of therapeutics to prevent cytotoxic autoantibodies from triggering disease in autoimmunity. The firm is focused on product development derived from in-house and from in-licensed candidates in the areas of oncology, autoimmunity, antibody engineering and infectious disease. This multi-faceted approach in developing both antibodies and vaccines provides a diversified strategy for creating novel immunotherapeutics in areas of unmet medical need.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
150-249
Revenue Range
15M-20M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NASDAQ : MGNX
IP Holdings
75-99

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2010 1 NIH $2,999,972
Project Title: Development of a Novel Bi-Specific Antibody Based Therapeutic that Simultaneously
2004 1 NIH $100,000
Project Title: Melanoma Proteins in Serum and Urine
2004 1 NIH $100,000
Project Title: Role of anti-Fc Gamma RIIB antibody in tumor clearance
2004 1 NIH $100,000
Project Title: Development of Novel Brucella Vaccine Candidates
2004 1 NIH $100,000
Project Title: Development of Soluble FcR-Ig Fusion Proteins

Key People / Management

  Scott Koenig -- Chief Exec. Officer, Pres and Director

  Ezio Bonvini -- Senior Vice President, Research

  Stacy E Ferguson

  Leslie S Johnson

  Syd Johnson

  Christopher T Rankin

  Michel Schummer

  Jeffrey B Stavenhagen

  Kathryn F Sykes

  Larry W Tjoelker

  Maria Concetta Veri

  Sujata Vijh

  Priska D Von Haller

Company News

There are no news available.